Poster: ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis

Journal article

Peer reviewed

Melhem Solh, Juan Pablo Alderuccio, Brian Hess, John Radford, Matt Lunning, David Ungar, Muneet Burke, Luqiang Wang and Kirit Ardeshna

Clinical lymphoma, myeloma and leukemia, Vol.21, pp.S238-S238

2021-09

Metrics

1 Record Views

Title: Poster: ABCL-362: Incidence, Onset, and Management of Myelosuppression in Patients Treated with loncastuximab Tesirine for R/R DLBCL in a Pooled Safety Analysis
Creators: Melhem Solh - Northside Hospital
Juan Pablo Alderuccio - Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA
Brian Hess - Medical University of South Carolina
John Radford - University of Manchester
Matt Lunning - University of Nebraska Medical Center
David Ungar - Adc Therapeutics
Muneet Burke - Adc Therapeutics
Luqiang Wang - Adc Therapeutics
Kirit Ardeshna - University College London Hospitals NHS Foundation Trust
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.21, pp.S238-S238
Publisher: Elsevier Inc
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031739956902976